JAK2 Gene Myelofibrosis Somatic Genetic Test
Cost: AED 4400.0
Test Details
The JAK2 gene is responsible for producing the Janus kinase 2 protein, which plays a crucial role in regulating the production and maturation of blood cells. Myelofibrosis is a rare blood disorder characterized by excessive fibrous connective tissue in the bone marrow. This condition is often associated with mutations in the JAK2 gene, specifically the JAK2 V617F mutation. This mutation causes the overactivation of the JAK2 protein, leading to abnormal cell growth and the accumulation of scar tissue in the bone marrow.
The JAK2 Gene Myelofibrosis Somatic Genetic Test is a type of genetic test that utilizes Next-Generation Sequencing (NGS) technology to analyze the DNA of blood cells. By identifying the presence of the JAK2 V617F mutation, this test can help diagnose myelofibrosis and differentiate it from other similar blood disorders.
Components
- Test Name: JAK2 Gene Myelofibrosis Somatic Genetic Test
- Price: AED 4400.0
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Cancer
- Doctor: Oncologist
- Test Department: Genetics
Pre Test Information
Before undergoing the JAK2 Gene Myelofibrosis Somatic Genetic Test, it is essential to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to create a pedigree chart of family members affected by the JAK2 Gene Myelofibrosis Somatic Genetic Test gene (JAK2).
Test Process
The JAK2 Gene Myelofibrosis Somatic Genetic Test is typically performed using a blood sample. The DNA in the sample is extracted and sequenced using advanced NGS technologies. The sequencing data is then analyzed to identify any mutations in the JAK2 gene.
Results and Treatment
If the JAK2 V617F mutation is detected, it confirms the presence of myelofibrosis and helps guide treatment decisions. Targeted therapies that specifically inhibit the overactive JAK2 protein can be considered as a treatment option for patients with this mutation.
It is important to note that the JAK2 Gene Myelofibrosis Somatic Genetic Test is just one tool used in the diagnosis and management of myelofibrosis. Other clinical and laboratory tests, such as bone marrow biopsy and complete blood count, are also typically performed to evaluate the extent of the disease and monitor its progression.
| Test Name | JAK2 Gene Myelofibrosis somatic Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for JAK2 Gene Myelofibrosis, somatic NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with JAK2 Gene Myelofibrosis, somatic NGS Genetic DNA Test gene JAK2 |
| Test Details | The JAK2 gene is a gene that provides instructions for making a protein called Janus kinase 2. This protein plays a role in signaling pathways that regulate the production and maturation of blood cells. Myelofibrosis is a rare blood disorder characterized by the excessive production of fibrous connective tissue in the bone marrow. It is often associated with mutations in the JAK2 gene, specifically a mutation known as JAK2 V617F. This mutation leads to the overactivation of the JAK2 protein, causing abnormal cell growth and the accumulation of scar tissue in the bone marrow. Somatic NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that analyzes the DNA of a specific gene or genes to identify mutations. In the case of JAK2 gene myelofibrosis, somatic NGS genetic testing can detect the presence of the JAK2 V617F mutation in the DNA of blood cells. This test can help diagnose myelofibrosis and differentiate it from other similar blood disorders. Somatic NGS genetic testing is typically performed using a blood sample. The DNA in the sample is extracted and sequenced using advanced sequencing technologies. The sequencing data is then analyzed to identify any mutations in the JAK2 gene. The results of the somatic NGS genetic test can provide valuable information for the diagnosis and management of myelofibrosis. If the JAK2 V617F mutation is detected, it confirms the presence of myelofibrosis and helps guide treatment decisions. Targeted therapies that specifically inhibit the overactive JAK2 protein can be considered as a treatment option for patients with this mutation. It is important to note that somatic NGS genetic testing is just one tool used in the diagnosis and management of myelofibrosis. Other clinical and laboratory tests, such as bone marrow biopsy and complete blood count, are also typically performed to evaluate the extent of the disease and monitor its progression. |
